

Craig P Nolan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8872898/publications.pdf>

Version: 2024-02-01

23
papers

1,961
citations

471509

17
h-index

677142

22
g-index

23
all docs

23
docs citations

23
times ranked

3399
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase I clinical trial of temsirolimus and perifosine for recurrent glioblastoma. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 429-436.	3.7	29
2	Phase II trial of an AKT inhibitor (perifosine) for recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2019, 144, 403-407.	2.9	55
3	Genomic Correlates of Disease Progression and Treatment Response in Prospectively Characterized Gliomas. <i>Clinical Cancer Research</i> , 2019, 25, 5537-5547.	7.0	107
4	Overview of metastatic disease of the central nervous system. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2018, 149, 3-23.	1.8	28
5	Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma. <i>Cancer Discovery</i> , 2017, 7, 1018-1029.	9.4	302
6	Bevacizumab in high-grade glioma patients following intraparenchymal hemorrhage. <i>Neuro-Oncology Practice</i> , 2017, 4, 24-28.	1.6	4
7	Molecular and Clinical Effects of Notch Inhibition in Glioma Patients: A Phase 0/I Trial. <i>Clinical Cancer Research</i> , 2016, 22, 4786-4796.	7.0	95
8	The confused oncologic patient: a rational clinical approach. <i>Current Opinion in Neurology</i> , 2016, 29, 789-796.	3.6	12
9	Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma. <i>Neuro-Oncology</i> , 2016, 18, 283-290.	1.2	161
10	R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. <i>Blood</i> , 2015, 125, 1403-1410.	1.4	267
11	Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. <i>Neuro-Oncology</i> , 2015, 17, 116-121.	1.2	207
12	Phase II Study of Bevacizumab, Temozolomide, and Hypofractionated Stereotactic Radiotherapy for Newly Diagnosed Glioblastoma. <i>Clinical Cancer Research</i> , 2014, 20, 5023-5031.	7.0	89
13	Intramedullary spinal cord and leptomeningeal metastases from intracranial low-grade oligodendroglioma. <i>Clinical Imaging</i> , 2014, 38, 505-507.	1.5	3
14	Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma. <i>Neuro-Oncology</i> , 2013, 15, 242-250.	1.2	83
15	Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer. <i>Journal of Neuro-Oncology</i> , 2010, 100, 443-447.	2.9	100
16	Myelopathies in Patients With Cancer. <i>Archives of Neurology</i> , 2010, 67, 298-304.	4.5	35
17	Pearls: Primary Brain Tumors. <i>Seminars in Neurology</i> , 2010, 30, 005-009.	1.4	1
18	Randomized Phase II Trial of Chemoradiotherapy Followed by Either Dose-Dense or Metronomic Temozolomide for Newly Diagnosed Glioblastoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 3861-3867.	1.6	159

#	ARTICLE	IF	CITATIONS
19	A phase II trial of vinorelbine and intensive temozolomide for patients with recurrent or progressive brain metastases. <i>Journal of Neuro-Oncology</i> , 2008, 87, 85-90.	2.9	40
20	Leptomeningeal Metastases from Leukemias and Lymphomas. , 2005, 125, 53-69.		21
21	Salvage temozolomide for prior temozolomide responders. <i>Cancer</i> , 2005, 104, 2473-2476.	4.1	79
22	Leukemic and lymphomatous meningitis: incidence, prognosis and treatment. <i>Journal of Neuro-Oncology</i> , 2005, 75, 71-83.	2.9	83
23	Lymphomatous Meningitis. <i>American Journal of Cancer</i> , 2002, 1, 423-434.	0.4	1